

## Special Issue

# 4D-Transcription in Inflammation and Disease

### Message from the Guest Editor

The scope of this Special Issue is to collect contributions to improve our understanding of the dynamic regulation of gene expressions in healthy, damaged or cancer cells and tissues in response to changing local conditions that are critical for the survival of organisms. Contributions should focus on dynamic molecular synergies of gene regulatory sequences, on the evolution in time and space of enhancer-promoter contacts, epigenetic modifications and large-scale arrangements and interactions of chromosome territories to fine-tune transcriptional responses and set new epigenetic configurations. In addition, contributions that explain how a single transcription factor (NF-kappaB, STATs, etc.) can univocally activate a selected transcriptional output in response to a specific signaling input out of many possible options (cytokines, growth factors, etc.) are most welcome. We will be happy to accept

- Original research papers reporting advances in the field
- Educated reviews on published data
- Critical discussions able to provide new interpretations

---

### Guest Editor

Dr. Alessandra Agresti

In vivo Chromatin and Transcription Group, San Raffaele Scientific Institute, Via Olgettina 60 I-20132 Milano, Italy

---

### Deadline for manuscript submissions

closed (30 November 2018)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/16706](https://mdpi.com/si/16706)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).